Thus, the Galectin-1 and Galectin-3 that could protect BCP-ALL cells during drug treatment is complicated in terms of origin, and both leukemia cells as well as stromal cells are a possible source of these Galectins. This evidence concerns the gene LGALS3 and acute lymphoblastic leukemia.